Skip to main content
SpringerLink
Log in

Apixaban cost effective versus warfarin for stroke prevention

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lopez-Lopez J, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017: j5808, No. 359, 28 Nov 2017. Available from: URL: https://doi.org/10.1136/bmj.j5058.

    Google Scholar 

  2. Ball J. Which anticoagulant for stroke prevention in atrial fibrillation? BMJ 2017: j5399, No. 359, 28 Nov 2017. Available from: URL: https://doi.org/10.1136/bmj.j5399.

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Apixaban cost effective versus warfarin for stroke prevention. PharmacoEcon Outcomes News 793, 8 (2017). https://doi.org/10.1007/s40274-017-4568-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4568-5

Search

Navigation